Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI+Avastin vs XELIRI+Avastin in mCRC
NCT00469443Phase 3Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Dec 2006
- Primary completion
- Feb 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in colorectal cancer (CRC), sponsored by Hellenic Oncology Research Group. Started Dec 2006; status: completed.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00469443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00469443.